A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer

NCT07736612 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer
RAS Mutations or Amplifications

Interventions

DRUG: HRS-2329 Tablet
DRUG: Nimotuzumab
DRUG: HS-20093
DRUG: Adebrelimab

Sponsor

Zhejiang University